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One of the most vexing problems in drug and device regula-
tion is "off-label" promotion-when a company markets uses for a
product that have not been approved by the US Food and Drug
Administration (FDA). Off-label use can range from conspicuous
(prescribing a product for an unapproved medical condition or pa-
tient group) to more subtle (prescribing beyond the approved dos-
age, duration, or any other parameter set forth in the approved
labeling). The challenge posed by off-label promotion derives from
a well-established dichotomy: the FDA has jurisdiction to regu-
late manufacturers and the claims they make about their prod-
ucts, but has no jurisdiction to regulate the practice of medicine
or physicians' prescribing behavior.I This dichotomy not only cre-
ates the temptation for companies to promote off-label uses, but
also creates a regulatory conundrum for the FDA.
The stakes are considerable. Companies earn billions from
off-label prescriptions, as physicians may prescribe products "in-
dependently from, and occasionally in defiance of, the approved
labeling."2 Such prescribing can be critical in certain therapeutic
areas, particularly those in which research findings greatly out-
pace the FDA approval process. 3 As such, off-label uses can be
common and evidence based.4 Indeed, off-label uses can even con-
stitute the standard of care in disciplines like oncology, neurology,
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I See 21 USC § 396.
2 Daniel Carpenter, Reputation and Power: Organizational Image and Pharmaceu-
tical Regulation at the FDA 617 (Princeton 2010).
3 See, for example, Amy P. Abernethy, et al, Systematic Review: Reliability of Com-
pendia Methods for Off-Label Oncology Indications, 150 Annals Internal Med 336, 336,
342 (2009).
4 See Buckman Co v Plaintiffs'Legal Committee, 531 US 341, 350 (2001); Aaron S.
Kesselheim and Michelle M. Mello, Prospects for Regulation of Off-Label Drug Promotion
in an Era of Expanding Commercial Speech Protection, in Holly Fernandez Lynch and I.
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and psychiatry. For example, off-label uses are so widespread in
oncology5 that federal law requires Medicare and Medicaid to re-
imburse for off-label uses of anticancer drugs if the use appears
in an official medical compendium.6
On the other hand, off-label uses also can be dangerous, can
be based on dubious evidence, and can inflate health spending. A
2006 study found that 73 percent of off-label uses by office-based
physicians "had little or no scientific support,"7 and a 2012 study
found that 79 percent of off-label uses by primary care physicians
"lacked strong scientific evidence."8 Thus, many worry that off-
label use can expose patients to considerable risks without corre-
sponding benefits.9 A more recent study found that off-label uses
were associated with a 44 percent greater likelihood of adverse
events than approved uses.10 Off-label promotion has led to "wide-
spread patient morbidity and mortality" for patients prescribed
drugs like rofecoxib (Vioxx), rosiglitazone (Avandia), and paroxe-
tine (Paxil), among others."1
As such, companies have paid tens of billions over the last
two decades to settle allegations of illegal off-label promotion. 12 In
fact, most major drug and device firms have settled such cases. 13
At the same time, the FDA has been admonished by Congress,
academics, and the media for not doing more to regulate off-label
promotion. 14
Glenn Cohen, eds, FDA in the Twenty-First Century: The Challenges of Regulating Drugs
and New Technologies 184, 185-86 (Columbia 2015).
5 See, for example, Michael Soares, "Off-Label" Indications for Oncology Drug Use
and Drug Compendia: History and Current Status, 1 J Oncology Prac 102, 104 (2005).
6 See 42 USC §§ 1395x(t)(2), 1396r-8(g)(1)(B)(i), (k)(6).
7 David C. Radley, Stan N. Finkelstein, and Randall S. Stafford, Off-Label Prescrib-
ing among Office-Based Physicians, 166 Archives Internal Med 1021, 1024 (2006).
8 Tewodros Eguale, et al, Drug, Patient, and Physician Characteristics Associated
with Off-Label Prescribing in Primary Care, 172 Archives Internal Med 781, 785 (2012).
9 See Kesselheim and Mello, Prospects for Regulation of Off-Label Drug Promotion
at 186 (cited in note 4); Henry A. Waxman, A History of Adverse Drug Experiences: Con-
gress Had Ample Evidence to Support Restrictions on the Promotion of Prescription Drugs,
58 Food & Drug L J 299, 305-306 (2003).
10 Tewodros Eguale, et al, Association of Off-Label Drug Use and Adverse Drug
Events in an Adult Population, 176 JAMA Internal Med 55, 58 (2016).
11 Kesselheim and Mello, Prospects for Regulation of Off-Label Drug Promotion at
186-87 (cited in note 4).
12 Sammy Almashat, Sidney M. Wolfe, and Michael Carome, Twenty-Five Years of
Pharmaceutical Industry Criminal and Civil Penalties: 1991 through 2015 *4-6 (Public
Citizen, Mar 31, 2016), archived at http://perma.cc/3B25-73BY.
13 See id at *47-49 (listing the amount and size of fines paid by pharmaceutical com-
panies from 1991 to 2015).
14 Carpenter, Reputation and Power at 618 (cited in note 2).
20161 125
2
University of Chicago Law Review Online, Vol. 83 [2017], Iss. 1, Art. 12
http://chicagounbound.uchicago.edu/uclrev_online/vol83/iss1/12
The University of Chicago Law Review Online
Given the stakes, then, it is surprising that the Federal Food,
Drug, and Cosmetic Acts (FDCA) "do[es] not expressly prohibit
the promotion or marketing of drugs for off-label use."16 Others
have also questioned the statutory basis for the prohibition. 17 The
FDA itself notes that "[p]romoting an approved drug for off-label
uses is not itself a prohibited act under the FDCA, nor is it an
element of any prohibited act." 18 Instead, the FDA argues, off-
label promotion "plays an evidentiary role in determining whether
a drug is misbranded." 19
Nevertheless, almost no one has seriously undertaken the
statutory question: Does the FDCA support the FDA's functional
ban on off-label promotion?20 This Essay answers yes. Although
the phrases "off-label" and "extra-label" are mentioned only once
each in Title 21, both in glancing ways, 21 I find that multiple sec-
tions of the FDCA either assume or contemplate a ban on off-label
promotion. I also find, using various tools of statutory construc-
tion, that the FDCA as a whole depends on the ban. Without it,
significant portions of the statute would be hollow or even non-
sensical, and the FDA's approval schemes-the lodestar of medi-
cal product regulation-would collapse under their own weight.
The statutory case against off-label promotion, then, is quite
complex, and requires a fair bit of description of the statute, the
FDA's logic, and how both evolved. The government must tailor
its statutory logic depending on whether the off-label promotion
qualifies as "labeling," "advertising," or something else, such as
oral statements. Part I, then, describes the many faces of promo-
tion, before turning to the detailed statutory logic that some off-
label promotion qualifies as labeling (Part II), as advertising
15 52 Stat 1040 (1938), codified at 21 USC § 301 et seq.
16 United States u Caronia, 703 F3d 149, 154 (2d Cir 2012) (quotation marks
omitted).
17 See generally Terry S. Coleman, Origins of the Prohibition against Off-Label Pro-
motion, 69 Food & Drug L J 161 (2014).
18 Brief and Special Appendix for the United States, United States V Caronia, Nos
09-5006-cr(L), 10-0750(CON), *51 (2d Cir filed Oct 8, 2010) (available on Westlaw at 2010
WL 6351497) ("Caronia Brief').
19 Id.
20 Terry Coleman provides by far the most probing analysis of the statutory basis for
the prohibition, but focuses on its historical origins and does not apply the tools of statu-
tory construction. See generally Coleman, 69 Food & Drug L J 161 (cited in note 17).
21 Only one section of Title 21 uses the phrase "off-label," in reference to a require-
ment that pediatric drug studies disclose both the "labeled and off-labeled" indications
being studied. 21 USC § 355a(f)(6)(B). The phrase "extra-label" is used once, in reference
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(Part III), or as oral statements (Part IV), respectively. The pay-
off, I hope, is a concise application of the tools of construction in
Part V. In short, the statutory case against off-label promotion is
complicated but compelling.
I. THE MANY FACES OF PROMOTION
Off-label promotion can take many forms. Because drug and
device markets can be highly competitive, firms have devised ever
more creative ways to promote their products. The classic sce-
nario is "detailing," when a sales representative visits a physi-
cian's office to discuss a product in person, sometimes leaving be-
hind written materials.22 Beyond detailing, firms have used
continuing medical education (CME) events 23 and paid for meals,
travel, or entertainment to promote products off-label.24 Compa-
nies have also paid prescribers as speakers, consultants, advisors,
or preceptors in order to suggest off-label uses for their products.25
Even more questionable practices include funding sham educa-
tional and research "grants" that involve unapproved uses, or
even hiring ghostwriters to publish journal articles discussing off-
label uses under the name of a respected "thought leader."26
And then, of course, there is the menu of more traditional ad-
vertisements via television, radio, and print, which are often used
as vehicles for suggesting off-label uses. More recently, the FDA
has confronted companies online, where they use Internet adver-
tising and social media to suggest off-label uses for their products.
For example, companies have purchased sponsored links and
search engine terms that suggest unapproved uses. 27
22 See Stephanie M. Greene, FDA Prohibitions on Off-Label Marketing Do Not Vio-
late Drug Manufacturers' First Amendment Rights, in Stephanie M. Greene and Lars
Noah, Debate, Off-Label Drug Promotion and the First Amendment, 162 U Pa L Rev
Online 239, 241 (2014).
23 Lars Noah, Permission to Speak Freely?, in Greene and Noah, Debate, 162 U Pa L
Rev Online at 248, 251 (cited in note 22).
24 See Duff Wilson, Novartis Settles Off-Label Marketing Case over 6 Drugs for $422.5
Million (NY Times, Sept 30, 2010), available at http://nyti.ms/1PDkgPR (visited Sept 14,
2016) (Perma archive unavailable).
25 See, for example, id.
26 See Carl Elliott, The Secret Lives of Big Pharma's 'Thought Leaders' (Chronicle of
Higher Education, Sept 12, 2010), archived at http://perma.cc/FX9G-XKL8.
27 See, for example, Jared A. Favole, FDA Warns Drug Firms over Internet Ads (Wall
St J, Apr 4, 2009), online at http://www.wsj.com/articles/SB123879766861188121 (visited
Sept 1, 2016) (Perma archive unavailable); Scott Gottlieb, FDA Regulates Internet Search
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Finally, companies frequently distribute to prescribers medi-
cal reference texts and journal article reprints that discuss off-
label uses-which are not labeling or advertising when written,
but may transform into such if used by the manufacturer
that way.
Thus, virtually every form of promotion is a potential vessel
for off-label messages. Yet, regardless of the form, rarely is the
message a singular, isolated event; typically it occurs as part of a
broader marketing scheme.28 The question for the government,
then, is whether these messages qualify as labeling, advertising,
or something else under the FDCA. The next three Parts (II-IV)
describe the statutory logic.
II. OFF-LABEL PROMOTION VIA LABELING
According to the FDA, off-label promotion via "labeling" can
violate both the new drug and misbranding sections of the stat-
ute. An important preface is that labeling is defined very broadly
to cover a wide variety of statements or claims made by or on be-
half of the manufacturer, in a wide variety of contexts. The FDCA
defines "labeling" as "all labels and other written, printed, or
graphic matter (1) upon any article or any of its containers or
wrappers, or (2) accompanying such article."29 The latter clause is
particularly important. Several early court decisions-including
some that predated the 1938 Act30--interpreted "accompanying"
to include materials that supplement or explain a product, even
if distributed separately from it.31 In fact, after Congress passed
the 1906 Pure Food and Drugs Act,32 companies frequently re-
moved controversial product claims from packaging and distrib-
uted them separately via brochures or circulars to evade FDA ju-
risdiction, which under the 1906 Act was limited to packaging.33
28 Nathan Cortez, Can Speech by FDA-Regulated Firms Ever Be Noncommercial?, 37
Am J L & Med 388, 413 (2011).
29 Federal Food, Drug, and Cosmetic Act (FDCA) § 201(m), 52 Stat 1040, 1041 (1938),
codified at 21 USC § 321(m).
30 See, for example, Seven Cases of Eckman's Alternative v United States, 239 US
510, 517-18 (1916) (discussing how putting false claims in an accompanying circular for a
product is still within reach of lawmaking power).
31 See Kordel v United States, 335 US 345, 349-50 (1948); United States v Urbuteit,
335 US 355, 356-57 (1948); VE. Irons, Inc v United States, 244 F2d 34, 39 (1st Cir 1957).
32 Pub L No 59-384, 34 Stat 768 (1906).
33 Coleman, 69 Food & Drug L J at 178-79 (cited in note 17).
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As concerns grew over companies giving false or misleading ma-
terials to physicians,34 the FDA defined "labeling" more broadly
by rule.35 Today, the FDA defines "labeling" as virtually any
"printed, audio, or visual matter" that describes a drug and is
"disseminated by or on behalf of [the] manufacturer."36
Defining "labeling" broadly is critical to the FDA's argument
that off-label promotion violates the FDCA. As construed by
courts, the content of the material determines whether it is label-
ing. Indeed, a recent case found that a company press release con-
stituted labeling.37 If off-label promotion qualifies as labeling, the
FDA can argue that the company violates the FDCA by introduc-
ing an unapproved "new drug" into interstate commerce, by mis-
branding the product, or both.
A. The "New Drug" Provisions
In some cases, the government alleges that off-label promo-
tion violates the "new drug" provisions of the FDCA. Sec-
tion 301(d) prohibits unapproved new drugs from being intro-
duced into interstate commerce, 38 and § 505(a) bans any "new
drug" not approved by FDA.39 Section 2 0 1 (p), in turn, defines "new
drug" to include any drug that the FDA has not approved "for use
under the conditions prescribed, recommended, or suggested in
the labeling."40 Reference to the labeling here makes it difficult
for the FDA to use the new drug provisions to prosecute off-label
34 See Part 22: Administered Prices in the Drug Industry (The Food and Drug Ad-
ministration: Dr. Henry Welch), Hearings before the Subcommittee on Antitrust and Mo-
nopoly of the Committee on the Judiciary, United States Senate, 86th Cong, 2d Sess 12081,
12100, 12104 (1960) (statement of Arthur S. Flemming, Secretary of Health, Education,
and Welfare); id at 12123 (statement of George P. Larrick, Commissioner of Food and
Drugs); Coleman, 69 Food & Drug L J at 189 (cited in note 17).
35 See Food and Drug Administration, Department of Health, Education, and Wel-
fare, Drugs; Statement of Ingredients; Prescription Drug Advertisements, 28 Fed Reg
6375, 6377 (1963), amending 21 CFR § 1. 105(1).
36 21 CFR § 202.1(1)(2).
37 See United States v Harkonen, 2009 WL 1578712, *9-13 (ND Cal). See also
William W. Vodra, Nathan G. Cortez, and David E. Korn, The Food and Drug Administra-
tion's Evolving Regulation of Press Releases: Limits and Challenges, 61 Food & Drug L J
623, 624-29 (2006) (describing "how FDA asserted jurisdiction over drug- and device-
related press releases through its authority over labeling, promotional labeling, and
advertising").
38 FDCA § 301(d), 52 Stat at 1042, codified at 21 USC § 331(d).
39 FDCA § 505(a), 52 Stat at 1052, codified at 21 USC § 355(a). FDA regulations also
declare that a drug is rendered an illegal "new drug" if a company promotes it for an un-
approved use. 21 CFR § 310.3(h).
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promotion via advertising or oral statements, 41 which I address
below. The new drug provisions are also less useful if the company
can argue that the drug is "generally recognized as safe and effec-
tive," in which case it is not a new drug at all, or if the drug is a
biologic approved under the Public Health Service Act42 rather
than the FDCA.43 Nevertheless, the broad definition of "labeling"
helps the FDA argue that products promoted off-label are unap-
proved new drugs.
B. Misbranding
More commonly, the FDA relies on the FDCA's misbranding
provisions to prosecute off-label promotion, though the statutory
case is much more attenuated.
First, off-label promotion that is false or misleading can mis-
brand a product under FDCA § 301(a), which prohibits introduc-
ing a misbranded product into interstate commerce. 44 Sec-
tion 502(a) provides that a product is misbranded "[i]f its labeling
is false or misleading in any particular." 45Although such an alle-
gation is relatively straightforward as a statutory matter, it can
be difficult for the government to prove. Typically, the off-label
claim is very much in dispute-scientifically, medically, factu-
ally-and so the government must show that the claim misleads.
Not surprisingly, then, most of the literature on off-label promo-
tion focuses on cases in which the claim is not necessarily false or
misleading.46
More frequently, the FDA must make a more attenuated,
multistep argument that the product is misbranded.47 This argu-
ment relies on the statutory requirement that product labeling
provide "adequate directions for use."48 The chain of reasoning re-
quires a fair bit of explanation.
Section 502(f)(1) declares a product misbranded unless its la-
beling bears "adequate directions for use."49 However, this section
41 Coleman, 69 Food & Drug L J at 162 (cited in note 17).
42 Pub L No 78-410, 58 Stat 682 (1944), codified at 48 USC § 201 et seq.
43 Coleman, 69 Food & Drug L J at 162 (cited in note 17).
44 FDCA § 30 1(a), 52 Stat at 1042, codified at 21 USC § 331(a). The FDA sometimes
uses FDCA § 301(k) for products that are misbranded while being held for sale, after ship-
ment in interstate commerce. 21 USC § 331(k). If misbranding is done "with the intent to
defraud or mislead," it is subject to additional penalty under 21 USC § 333(a)(2).
45 FDCA § 502(a), 52 Stat at 1050, codified at 21 USC § 352(a).
46 See, for example, Coleman, 69 Food & Drug L J at 162 n 2 (cited in note 17).
47 Consider FDCA § 502, 52 Stat at 1050-51, codified at 21 USC § 352.
48 FDCA § 502(f)(1), 52 Stat at 1051, codified at 21 USC § 352(f)(1).
49 FDCA § 502(f)(1), 52 Stat at 1051, codified at 21 USC § 352(f)(1).
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exempts drugs and devices for which adequate directions are "not
necessary for the protection of the public health." 50 The FDA has
interpreted this to exempt all prescription drugs, thus requiring
adequate directions only for over-the-counter drugs.51 By rule, the
FDA has created a series of conditions to qualify for the
exemption.52
Instead of adequate directions, the FDA expects prescription
drugs to provide "adequate information" for safe use by practi-
tioners.53 Thus, labeling must include all "indications" for the
drug, "including all purposes for which it is advertised or repre-
sented." 54Moreover, the regulations require that any labeling
that mentions the uses or dosages for the product may not deviate
from the uses and dosages specified in the FDA-approved physi-
cian labeling.55 Providing "adequate information" for prescribers,
then, means including information about "indications, effects,
dosages, routes, methods, and frequency and duration of admin-
istration."56 All labeling must use the "same [] language and em-
phasis" and must be "consistent with and not contrary to" the
FDA-approved labeling.57
Thus, failure to list all indications for the product or failure
to use the same language used in the approved labeling can mis-
brand the product and jeopardize its exemption from the "ade-
quate directions" requirement in § 502(f)(1). 58 In essence, to be ex-
empt, any labeling for prescription drugs must disclose all
intended uses; otherwise, the product is misbranded.
Importantly, FDA regulations declare that the manufac-
turer's intended uses can be gleaned from a variety of sources,
including "labeling [ ], advertising [ ], or oral or written state-
ments."5o As these regulations make clear, "intended use" is the
"objective intent of the persons legally responsible for the label-
ing" of the product, and can be determined by their "expressions,"
including "labeling claims, advertising matter, or oral or written
statements by such persons or their representatives."60 Objective
50 FDCA § 502(f)(1), 52 Stat at 1051, codified at 21 USC § 352(f)(1).
51 21 CFR § 201.100.
52 21 CFR § 201.5.
53 21 CFR § 201.100(c)(1), (d)(1).
54 21 CFR § 201.100(c)(1).
55 21 CFR § 201.100(d)(1).
56 21 CFR § 201.100(d)(1).
57 21 CFR § 201.100(d)(1).
58 21 CFR §§ 201.100(c)(1), (d)(1), 201.128.
59 21 CFR §201.128.
60 21 CFR §201.128.
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intent can also be determined "by the circumstances surrounding
the distribution" of the product.61 Thus, a company's knowledge
that its product is "offered and used for a purpose for which it is
neither labeled nor advertised" can be evidence of intent.62
This "incorporation-by-reference theory"63 creates a catch-22,
or what observers call the "squeeze play" against off-label promo-
tion: companies that do not disclose off-label uses in their physi-
cian labeling misbrand the product by failing to provide adequate
directions for laypersons or adequate information for prescribers;
but companies that try to amend their labeling to provide such
information misbrand the product or cause the product to be an
unapproved new drug.64
This interpretation "encountered little resistance from the
courts," and "may be the most powerful tool that FDA has against
most forms of off-label promotion."65 The FDA developed this ar-
gument shortly after Congress passed the FDCA in 1938.66 It be-
gan as a rule to require labeling to include adequate directions for
indications claimed in advertising.67 In the 1938 Act, Congress
had chosen to vest authority over advertising for FDA-regulated
products with the Federal Trade Commission rather than the
FDA, over the FDA's bitter opposition.68 Thus, the statutory basis
for the FDA's 1938 regulation was questionable. In fact, it took
almost a decade for the FDA to test it in court.69
A skeptical Justice Department asked the FDA to explain its
authority.70 The response, though unavailable, most likely relied
on the idea held by FDA officials then that the agency would not
be challenging advertising claims themselves, but instead would
use those claims as evidence to challenge deficiencies in the prod-
uct's labeling (the failure to include adequate directions).71 FDA
61 21 CFR § 201.128.
62 21 CFR §201.128.
63 See Coleman, 69 Food & Drug L J at 228 (cited in note 17).
64 See id at 196.
65 Id at 193.
66 Food and Drug Administration, Promulgation of Regulations under the Federal
Food, Drug, and Cosmetic Act and Repeal of Certain Regulations Heretofore Promulgated
Thereunder, 3 Fed Reg 3161, 3167 (1938). The FDA formalized the "intended use" doctrine
in 1944. Food and Drug Administration, Regulations for the Enforcement of the Federal
Food, Drug, and Cosmetic Act, 9 Fed Reg 12255, 12256-57 (1944).
67 3 Fed Reg at 3167 (cited in note 66).
68 Coleman, 69 Food & Drug L J at 171-76 (cited in note 17). Congress reversed this
position in 1962. See generally Drug Amendments of 1962, Pub L No 87-781, 76 Stat 780.
69 Coleman, 69 Food & Drug L J at 194 (cited in note 17).
70 Id at 194 & n 208 (citing a 1946 letter from Assistant Attorney General Theron L.
Caudle to Assistant General Counsel of the Federal Security Agency Daniel P. Willis).
71 Id at 195 (cited in note 17).
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officials explained that before the 1938 regulation was published,
the agency had sent a draft to the House of Representatives leg-
islative counsel, "who apparently had no objections, thus dem-
onstrating that the regulation was consistent with congressional
intent." 72 A few years later, a court accepted the FDA's argument
that "adequate directions" focused on labeling deficiencies rather
than impermissible advertising claims.73
Eventually, the FDA pushed the theory even further, arguing
that a series of health lectures for a company could be used as
evidence of intent.74 The agency argued that the company mis-
branded the products by failing to include adequate directions for
the uses discussed during the lectures.75 Because the lectures
could not be "labeling," the FDA argued that they were relevant
only to show intended use, and that the drugs were misbranded
only because their labeling failed to state their uses as required
by the Act.76 The court agreed.77
Emboldened by these victories, the FDA amended the regu-
lation to require adequate directions not only for uses suggested
in advertising, but also for uses suggested in other contexts. The
modern "squeeze play," then, derives from the FDA's very early
aggressive interpretation of the Act, which was driven by its ini-
tial lack of jurisdiction over advertising.78
III. OFF-LABEL PROMOTION VIA ADVERTISING
If off-label promotion occurs via advertising rather than la-
beling, the FDA can allege violations of multiple sections of the
FDCA-again, none of which explicitly prohibits such promotion.
First, § 303(g) of the Act prohibits direct-to-consumer advertising
that is false or misleading,79 which might form the basis for a
straightforward complaint. But, as noted above, such claims are
difficult to prosecute if they are at all subject to unsettled or con-
flicting scientific evidence.
72 Id.
73 See Alberty Food Products u United States, 194 F2d 463, 464 (9th Cir 1952).
74 See Coleman, 69 Food & Drug L J at 194 (cited in note 17).
75 Id at 196 (citing a 1947 letter from Acting Assistant General Counsel, Federal Se-
curity Agency, Alvin M. Loverud to Assistant US Attorney Harry C. Blanton).
76 Id (citing a 1947 letter from Acting Assistant General Counsel, Federal Security
Agency, Alvin M. Loverud to Assistant US Attorney Harry C. Blanton).
77 United States u 150 Packages, etc, Labeled in Part Bush Mulso Tablets, 83 F Supp
875, 880 (ED Mo 1947).
78 Coleman, 69 Food & Drug L J at 196 (cited in note 17).
79 Food and Drug Administration Amendments Act of 2007 § 503(g), Pub L No 110-
85, 121 Stat 823, 940, amending § 303(g) of the FDCA and codified at 21 USC § 333(g).
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Second, § 502(n) of the Act authorizes the FDA to ensure that
prescription drug advertisements are not misbranded.80 This sec-
tion does not mention off-label promotion; instead, it requires ad-
vertisements to give either a "brief summary relating to side ef-
fects, contraindications, and effectiveness,"81 or in the case of
television or radio ads provide a "major statement" of side effects
and contraindications.82 The word "effectiveness" in § 502(n) can
be read as requiring that advertisements briefly summarize the
approved indications. Indeed, the FDA by rule declares that an
advertisement for a prescription drug is false, misleading, lacks
fair balance, or otherwise violates § 502(n) if it "[c]ontains a rep-
resentation or suggestion, not approved or permitted for use in
the labeling, that a drug is better, more effective, [or] useful in a
broader range of conditions or patients . . . than has been dem-
onstrated by substantial evidence or substantial clinical experi-
ence."83 More directly, the rule also prohibits prescription drug
advertisements from recommending or suggesting "any use that
is not in the labeling accepted in [the] new-drug application or
supplement."84
Thus, as with the regulations prohibiting off-label promotion
in labeling, the regulations prohibiting off-label promotion in ad-
vertising derive from broadly worded statutory text that is not at
all explicit on the point.85
IV. OFF-LABEL PROMOTION VIA ORAL STATEMENTS
Finally, if the off-label claims are made via oral statements,
then the FDA must use even different statutory logic. As with
claims made via labeling, the FDA uses a complicated squeeze
play, relying on the adequate directions requirement in
§ 502(f)(1). Again, the squeeze play puts companies in a catch-22:
one can misbrand a product by failing to provide adequate direc-
tions for laypersons or adequate information for prescribers, or
80 Drug Amendments of 1962 § 131, 76 Stat 780, 791, codified at 21 USC § 352(n).
81 Drug Amendments of 1962 § 131, 76 Stat at 791-92, codified at 21 USC § 352(n).
82 FDA Amendments Act of 2007 § 301, 121 Stat at 940, codified at 21 USC § 352(g).
83 21 CFR § 202.1(e)(6)(i).
84 21 CFR § 202.1(e)(4)(i)(a).
85 Some argue that the FDA's expansive interpretation of "labeling" has erased any
meaningful distinction between advertising and labeling. See, for example, Coleman, 69
Food & Drug L J at 191-92 (cited in note 17). Sometimes, the FDA alleges violations of
both sets of regulations. See, for example, Thomas Abrams, Director of the Division of
Drug Marketing, Advertising, and Communications, FDA, Letter to Reinhard Franzen,
President and Chief Executive Officer, Bayer HealthCare Pharmaceuticals, Inc *1 (Oct 3,
2008), archived at http://perma.cc/WX4R-HYUE.
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one can amend the labeling to include off-label uses and thus mis-
brand the product or create an unapproved new drug.86
Again, the intended use doctrine87 allows the FDA to take ac-
tion against marketers based on the content of their communica-
tions, without necessarily asserting jurisdiction over the commu-
nications themselves,88 a distinction recently rejected by the
Second Circuit.89 FDA regulations extend this logic to oral state-
ments, even though such statements are not "written, printed, or
graphic matter" that would qualify as "labeling."90 Indeed, the
FDA rule that defines "adequate directions" makes clear that in-
tended uses include uses suggested orally.91 As such, FDA warn-
ing letters have objected to oral presentations by sales represent-
atives in physicians' offices, at exhibit booths, or before formulary
boards.92
An important caveat here is First Amendment doctrine. The
Second Circuit recently sustained a First Amendment defense by
Alfred Caronia, a sales representative who had been convicted for
promoting the narcolepsy drug Xyrem for unapproved indications
such as fibromylagia, muscle disorders, and chronic pain.93 He
was surreptitiously recorded discussing these and several other
off-label uses for Xyrem. The court found that the FDA had
"treated promotional speech as more than merely evidence of a
drug's intended use," and had "construed the FDCA to prohibit
promotional speech as misbranding itself."94 Apparently, this is a
matter of degree-the Second Circuit emphasized the extent to
which the government objected to Caronia's speech in its briefs
and during trial, in comparison to how little it focused on the stat-
utory violation.9 The dissent argued that drug regulation has re-
lied on intended use for over a century, and that courts have used
86 See Peter Barton Hutt, Richard A. Merrill, and Lewis A. Grossman, Food and
Drug Law 930-31 (Foundation 4th ed 2014).
87 21 CFR § 201.128 (defining "intended uses" for drugs); 21 CFR § 801.4 (defining
"intended uses" for devices).
88 Vodra, Cortez, and Korn, 61 Food & Drug L J at 627 (cited in note 37).
89 United States u Caronia, 703 F3d 149, 155 (2d Cir 2012).
90 FDCA § 201(m), 52 Stat at 1041, codified at 21 USC § 321(m).
91 21 CFR § 201.5(a).
92 Vodra, Cortez, and Korn, 61 Food & Drug L Jat 627 (cited in note 37) (citing
letters).
93 Caronia, 703 F3d at 152.
94 Id at 155.
95 Id at 160-62 (noting that "[t]he government never suggested, for example, that
Caronia conspired to place false or deficient labeling on a drug" and that "the government
prosecuted Caronia for his promotion and marketing efforts" and holding that "the gov-
ernment [ ] prosecute[d] Caronia for his speech").
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oral representations as evidence of intent for nearly as long.96
Thus, after United States v Caronia,97 oral statements may have
additional cover from FDA regulation.
V. APPLYING TOOLS OF CONSTRUCTION TO THE FDCA
The FDA clearly views off-label promotion as evidence of stat-
utory violations. But how does the FDA's position fare when sub-
jected to the tools of statutory construction? Almost no one has
seriously undertaken the task. The Second Circuit's statutory
analysis in Caronia is perfunctory,98 though later decisions have
latched onto it." Because companies typically challenge the FDA's
prohibition on First Amendment rather than statutory grounds,
most opinions logically focus on free speech doctrine. One goal of
this Essay, then, is to provide a more concerted statutory
analysis.
A. Chevron Deference
As a threshold matter, the FDA's interpretation of the FDCA,
a statute the agency is charged with administering, would be sub-
ject to Chevron deference from courts. 100 And under Chevron
U.S.A. Inc v Natural Resources Defense Council, Inc,101 courts
must defer to an agency's construction of an ambiguous statute if
the interpretation is reasonable.102 For the sake of space, and to
avoid duplicative analysis, I address the two-step test under
Chevron as a single inquiry: Is the FDA's interpretation of the Act
reasonable?103
96 Id at 169-70 (Livingston dissenting), citing Pure Food and Drugs Act of 1906, 34
Stat 768. See also United States v Eleven Cartons of Drug Labeled in Part "Vapex", 59 F2d
446, 448 (D Md 1932); VE. Irons, Inc v United States, 244 F2d 34, 44 (1st Cir 1957).
97 703 F3d 149 (2d Cir 2012).
98 Id at 154-55, 160.
99 See, for example, Amarin Pharma, Inc v United States Food & Drug Administra-
tion, 119 F Supp 3d 196, 203-05 (SDNY 2015) (citing Caronia and its analysis of the
FDCA); Schuler v Medtronic, Inc, 2014 WL 988516, *1 (CD Cal).
100 See generally Chevron U.S.A. Inc v Natural Resources Defense Council, Inc, 467
US 837 (1984). Under United States v Mead Corp, 533 US 218 (2001), there are numerous
indicia that Congress, through the FDCA, intended to delegate lawmaking authority to
the FDA here.
101 467 US 837 (1984).
102 Id at 842-43.
103 The Chevron two-step first asks whether Congress "has directly spoken to the pre-
cise question at issue," and then, if it has not, asks whether the agency's interpretation is
"based on a permissible construction of the statute." Id. Some scholars argue that Chevron
is really one step. See generally Matthew C. Stephenson and Adrian Vermeule, Chevron
Has Only One Step, 95 Va L Rev 597 (2009).
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B. The Text
The text of the FDCA, as detailed above, broadly prohibits
misbranding and introducing unapproved new products into in-
terstate commerce, 104 and broadly defines "labeling," which is
used to determine both types of violations 105 Although these pro-
visions do not expressly prohibit off-label promotion, these and
other provisions do broadly authorize the FDA to establish the
conditions under which drugs and devices may be legally mar-
keted.106 Indeed, former FDA Chief Counsel Peter Barton Hutt
once declared that "the Act must be regarded as a constitution"
that "establishes a set of fundamental objectives ... without at-
tempting to specify every detail of regulation." 107 Although courts
have questioned in egregious cases how far this principle can
stretch,108 they have generally confirmed the FDA's broad
authority.
Moreover, contrary to the Second Circuit's very cursory
analysis, 109 the FDCA is not completely silent on off-label market-
ing. Multiple sections contemplate or assume a ban on it. Under
a section titled "Practice of Medicine," the Act states that
"[n]othing in this chapter shall be construed to limit or interfere
with the authority of a health care practitioner to prescribe or ad-
minister any legally marketed device to a patient for any condi-
tion or disease." 110 Thus, the FDCA specifically contemplates off-
label prescribing of medical products. However, the same provi-
sion continues: "This section shall not limit any existing authority
of the Secretary to establish and enforce restrictions on the sale
or distribution, or in the labeling, of a device. . . . Further, this
section shall not change any existing prohibition on the promotion
of unapproved uses of legally marketed devices."111 Thus, Con-
gress recognized in the text of the FDCA itself an "existing prohi-
bition" against off-label promotion.
104 See Part II.
105 See Part II.
106 Food and Drug Administration Modernization Act of 1997 (FDAMA) § 406, Pub L
No 105-115, 111 Stat 2296, 2369, codified at 21 USC § 393(b).
107 Peter Barton Hutt, Philosophy of Regulation under the Federal Food, Drug and
Cosmetic Act, 28 Food Drug Cosmetic L J 177, 178 (1973).
108 See, for example, FDA u Brown & Williamson Tobacco Corp, 529 US 120, 155-56
(2000) (ruling that the FDCA does not authorize the FDA "to regulate tobacco products as
customarily marketed").
109 See Caronia, 703 F3d at 154-55.
110 FDAMA § 214, 111 Stat at 2348, codified at 21 USC § 396.
111 FDAMA § 214, 111 Stat at 2348, codified at 21 USC § 396 (emphasis added). This
section was part of the 1938 Act and was amended in 1997 and 2009. See FDAMA § 214,
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The FDCA also nods to off-label use in another section au-
thorizing unapproved uses of approved products in emergen-
cies. 112 Here, the statute defines "unapproved use of an approved
product" as use of a product that is "is approved, licensed, or
cleared under [the FDCA], but which use is not under such provi-
sion an approved, licensed, or cleared use of the product." 113 The
section then sets forth extensive criteria for the FDA to grant au-
thorization for emergency off-label uses, 114 including limited ad-
vertising and promotion for such. 115 This is strong evidence that
Congress read the Act as empowering the FDA to prohibit off-
label promotion.
C. Whole Act Rule
Although there are dozens of canons of construction, 116 a few
seem especially pertinent here. First, the "whole act rule" and its
corollaries tell courts to construe statutory provisions in light of
the entire statute, rather than in isolation. 117 Courts should avoid
constructions that are inconsistent with the overall structure of
the statute, with other provisions, or with subsequent
amendments. 118
When considering the FDCA as a whole, one can find dozens
of provisions that would make little sense if off-label promotion
were widely permissible. In particular, the "new drug" provisions
in § 505,119 which span dozens of pages and include dozens of sub-
sections, would be seriously undermined without such a prohibi-
tion. Section 505 creates a comprehensive system for manufactur-
ers to conduct clinical trials and submit "substantial evidence
that the drug will have the effect it purports or is represented to
111 Stat at 2348; Family Smoking Prevention and Tobacco Control Act § 101(b)(2), Pub L
No 111-31, 123 Stat 1776, 1784 (2009).
112 21 USC § 360bbb-3.
113 21 USC § 360bbb-3(a)(2)(B), (4)(E).
114 21 USC § 360bbb-3.
115 21 USC § 360bbb-3(e)(4).
116 See generally Antonin Scalia and Bryan A. Garner, Reading Law: The Interpreta-
tion of Legal Texts (Thomson/West 2012). See also William N. Eskridge Jr, Philip P.
Frickey, and Elizabeth Garrett, Cases andMaterials on Legislation: Statutes and the Cre-
ation of Public Policy, Appx B at 19-41 (Thomson/West 4th ed 2007).
117 See, for example, Gonzales u Oregon, 546 US 243, 273-74 (2006) (rejecting an in-
terpretation of the Controlled Substances Act by the attorney general in part because the
interpretation failed to consider the Act as a whole).
118 See, for example, Ledbetter u Goodyear Tire & Rubber Co, 550 US 618, 629-30
(2007) (interpreting the statute of limitations in Title VII of the Civil Rights Act in light
of the integrated enforcement scheme created by Title VII); Gonzales, 546 US at 257-58.
119 FDCA § 505, 52 Stat at 1052, codified at 21 USC § 355.
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have under the conditions of use prescribed, recommended, or
suggested in the proposed labeling thereof." 120 The statute defines
"substantial evidence" as "adequate and well-controlled investi-
gations."121 Given that most off-label claims are supported by
something far less than "adequate and well-controlled investiga-
tions," interpreting the Act to permit such promotion would un-
dermine "supplemental applications," which are mentioned nu-
merous times in the statute. Indeed, the FDCA includes forty-five
separate sections that refer to "new drugs" and seventeen sections
that refer to "supplemental applications."122 Moreover, massive
parts of the Code of Federal Regulations are predicated on these
authorities and have been in use for decades.123 Thus, these stat-
utory provisions endow the FDA with important gatekeeping au-
thority over new drugs, including the conditions under which they
can be legally marketed.124
That said, it is somewhat odd that the prohibition against off-
label promotion is buried in the statutory requirement that prod-
ucts must provide adequate directions for use. 125 But, again, this
is most likely a remnant of the original struggle by the FDA to
overcome limits in its legal authority over drug advertising. 126
D. Avoiding Absurdity
Another canon invoked by courts is to avoid statutory inter-
pretations that create absurd results. 127 One can argue that the
FDCA should be interpreted to prohibit off-label promotion be-
cause it would be absurd not to. The most salient feature of FDA
regulation over pharmaceuticals is its gatekeeping author-
ity-the authority to require manufacturers to conduct clinical
trials and show "substantial evidence" that a drug is safe and ef-
fective for its intended uses. 128 The new drug approval system,
120 Drug Amendments of 1962 § 102(c), 76 Stat at 781, codified at 21 USC § 355(d).
121 Drug Amendments of 1962 § 102(c), 76 Stat at 781, codified at 21 USC § 355(d).
122 This count is based on a search performed on Chapter 9 of Title 21 of the US Code
(the FDCA).
123 See, for example, 21 CFR Pts 310, 312, 314. 21 CFR § 314.70(a)(1)(i) establishes
criteria for filing supplemental applications to seek FDA approval for "each change in each
condition established in an approved application."
124 See Carpenter, Reputation and Power at 608-10 (cited in note 2).
125 Coleman, 69 Food & Drug L J at 198 (cited in note 17).
126 Id.
127 See, for example, Green u Bock Laundry Machine Co, 490 US 504, 509-11 (1989)
(finding that Federal Rule of Evidence 609(a)(1) could not be read literally, as it would
create "odd" or absurd results).
128 21 USC §§ 355, 393(b)(2)(B).
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then, is the centerpiece of pharmaceutical regulation. 129 Indeed,
when the government's interest in prohibiting off-label claims is
at issue, typically in First Amendment cases, 130 the FDA often ar-
gues that its entire drug approval scheme relies on the ability to
identify intended uses. Without it, companies would have little
incentive to conduct clinical trials and file supplemental new drug
approval applications for new uses. Companies instead would
have an incentive to seek the narrowest and least controversial
uses for initial approval, then easily expand the product's indica-
tions through aggressive marketing. Unsubstantiated claims
would flood the drug market, much like they do the market for
dietary supplements,131 which are not subject to premarket re-
view. It is no accident, then, that the government's interest in reg-
ulating off-label promotion and preserving the drug approval sys-
tem is virtually always found to be "substantial" for First
Amendment purposes. 132
The prohibition against off-label promotion is thus key to the
integrity of the drug approval scheme that the FDCA constructs
so carefully. 133 Without evidence of intended use, "this regulatory
machinery for protecting patients from unsafe and ineffective
drugs would be drastically impaired." 134 It would also draw into
question not only the century-old intended use doctrine, but also
the very definitions of "drug" and "device," which also depend on
intent.135 Moreover, if the FDA knew that once a drug was ap-
proved, it could be legally marketed for any use, the agency might
weigh the benefits and risks less charitably in the first instance. 136
Surely this must be an absurd result.
E. The Avoidance Canon
The Second Circuit in Caronia invoked the canon of constitu-
tional avoidance to construe the FDCA as not prohibiting "mere
129 Brown & Williamson, 529 US at 133; Carpenter, Reputation and Power at 608
(cited in note 2).
130 See, for example, Washington Legal Foundation v Henney, 202 F3d 331, 332-34
(DC Cir 2000).
131 See Paul A. Offit, Do You Believe in Magic? The Sense and Nonsense of Alternative
Medicine 64-107 (HarperCollins 2013).
132 See, for example, Caronia, 703 F3d at 165-66; Thompson v Western States Medical
Center, 535 US 357, 369 (2002).
133 See Caronia Brief at *61 (cited in note 18).
134 Id at *61-62.
135 21 USC § 321(g)(1), (h).
136 See, for example, Caronia, 703 F3d at 179 (Livingston dissenting).
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off-label promotion," on the logic that "such a construction would
raise First Amendment concerns." 137 The avoidance canon directs
courts to choose interpretations that would not render the statute
unconstitutional or raise serious questions about its constitution-
ality. 138 On first glance, because the Second Circuit indeed found
a First Amendment violation, it is not surprising that the court
invoked the canon. But on second glance, it is curious to rely heav-
ily on the avoidance canon here. For decades, courts have con-
strued the FDCA in light of First Amendment limitations.139
Moreover, Caronia was an as-applied challenge rather than a fa-
cial challenge. The court was asked whether the FDA's policy, ap-
plied to Caronia, violated his First Amendment rights, not
whether the FDCA permitted the FDA's policy as a threshold
matter. 140 Thus, although technically not prevented from relying
on the avoidance canon, it seems bizarre to invoke it without con-
sidering other tools of construction.
F. Congressional Approval or Acquiescence
A complementary argument is that the FDA's interpretations
are old and well-established, yet Congress has never seen fit to
amend the statute otherwise, suggesting Congress has acquiesced
to the FDA's position. 141 Congress has amended the FDCA more
than one hundred times since 1938,142 and not once did it feel the
need to clarify or reject the prohibition against off-label
promotion.
If one is not persuaded that Congress can endorse the FDA's
position by inaction, then consider past congressional action. In
1997, Congress affirmed the FDA's position when it passed the
137 Id at 160.
138 See, for example, Edward J. DeBartolo Corp v Florida Gulf Coast Building &
Construction Trades Council, 485 US 568, 575 (1988) (refusing to interpret the National
Labor Relations Act as prohibiting unions from distributing handbills in certain circum-
stances, as it would raise First Amendment free speech problems).
139 For an early example, see United States v Article of Drug Designated B-Complex
Cholinos Capsules, 362 F2d 923, 927 (3d Cir 1966) (rejecting a manufacturer's argument
that the FDA's use of statements as evidence of intent was "an expansion of the power and
jurisdiction of the [FDA] into areas of free speech").
140 Caronia, 703 F3d at 162-69.
141 For an example of a similar argument, see Bob Jones University v United States,
461 US 574, 599-602 (1983) (finding a strong case that Congress acquiesced to the IRS's
interpretation of the Internal Revenue Code). But see Brown & Williamson, 529 US at 155
(finding that Congress did not acquiesce to the FDA's new position on whether the FDCA,
unamended, granted it authority to regulate tobacco products).
142 Hutt, Merrill, and Grossman, Food and Drug Law at 11 (cited in note 86).
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Food and Drug Administration Modernization Act of 1997143
(FDAMA). Section 401 allowed manufacturers to disseminate cer-
tain information on off-label uses under carefully prescribed cir-
cumstances, "[n]otwithstanding sections 301(d), 502(f), and 505"
of the FDCA. 144 The clear implication was that these three sec-
tions otherwise prohibited off-label promotion. FDAMA § 401
thus exempted qualifying materials from being considered as ev-
idence of a new intended use. 145 Moreover, the law declared that
dissemination of qualifying materials "shall not be considered ...
as labeling, adulteration, or misbranding." 146 Thus, through duly
enacted legislation, Congress assumed that the FDCA prohibited
off-label promotion, and in fact crafted a narrow exemption from
the prohibition. The only "prohibited act" FDAMA added to the
FDCA was to declare it a misbranding violation to disseminate
off-label information in violation of the new exemption. 147
CONCLUSION
The FDA's "prohibition" against off-label promotion has been
questioned numerous times, but few have engaged in a rigorous
analysis of its statutory foundation, particularly applying tools of
construction. Applying these tools and engaging in a close textual
analysis reveals a complex but compelling statutory case. Almost
eighty years ago, Congress endowed the FDA with broad powers
via a broadly worded statute. For just as long, both the agency
and the courts have interpreted those powers accordingly to ad-
dress emerging problems. Congress, in turn, has incorporated
these interpretations, including the functional ban on off-label
promotion. As a result, subsequent amendments to the FDCA ei-
ther assume or contemplate a prohibition against off-label promo-
tion. This long evolution has created a complex statutory basis for
prohibiting off-label promotion, but a solid basis nonetheless.
143 Pub L No 105-115, 111 Stat 2296.
144 FDAMA § 401(a), 111 Stat at 2356-58, expired in 2006, citing also Public Health
Service Act § 351, Pub L No 78-410, 58 Stat 682, 702 (1944). These amendments were
subject to a statutory sunset in 2006. FDAMA § 401(e), 111 Stat at 2364. Section 401, of
course, was invalidated on First Amendment grounds in Washington Legal Foundation u
Friedman, 13 F Supp 2d 51 (DDC 1998), until the FDA interpreted it as a "safe harbor"
rather than a legal prohibition. Henney, 202 F3d at 335.
145 FDAMA § 401(a), 111 Stat at 2363.
146 FDAMA § 401(a), 111 Stat at 2363.
147 FDAMA § 401(b), 111 Stat at 2364.
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